Report Date: Friday, July 24, 2026, 9:00 a.m. CT Fiscal Period: Q2 2026 (quarter ended June 30, 2026)
Unlike most earnings previews, investors already know the headline numbers. HCA pre-announced preliminary Q2 results and cut full-year guidance on July 14, ten days before the actual call — a rare move that sent the stock down as much as 9.4% intraday, its largest drop since April and lowest intraday print in about a year. Shares closed around $376.54 on July 23, roughly 20% below where they started the year and well off the ~$545 high hit in February/March 2026.
That means the July 24 call is less about "will they beat or miss" and more about filling in the details, defending the guidance cut, and convincing investors this is a manageable, not spiraling, problem.
| Metric | Q2 2026 | Q2 2025 | vs. Consensus |
|---|---|---|---|
| Revenue | $20.23B | $18.605B | Beat (~$19.4–19.5B est.) |
| Net income attributable to HCA | $1.699B | $1.653B | — |
| Diluted EPS | $7.62 ($7.59 adj.) | $6.83 | Beat (~$7.46–7.47 est.) |
| Adjusted EBITDA | $4.027B | $3.849B | — |
| Adjusted EBITDA margin | 19.9% | 20.7% | Down ~80 bps |
Volume trends (same-facility, YoY): - Admissions +2.5%; equivalent admissions +2.7%; ER visits +3.6% - Inpatient surgeries -2.3%; outpatient surgeries -3.4%
So top-line growth (+9%) and reported EPS actually beat Wall Street estimates. The stock fell anyway because of what's happening below the headline — and because of what it implies for the rest of the year.
Two offsetting forces drove the quarter, and management flagged both clearly in the release:
Headwind — ACA exchange payer-mix shift: An increase in uninsured volume, primarily from patients losing coverage on ACA health insurance exchanges, created an estimated $400 million unfavorable impact on pretax income in Q2 (including a $75M true-up from Q1). This forced a major revision to the full-year exchange-impact assumption — from $600–900 million to $1.0–1.2 billion unfavorable for 2026. Management also flagged a smaller drag from declining surgical (service-mix) volume.
Tailwind — Medicaid Supplemental Payment Programs: HCA recognized ~$400 million of incremental net benefit, largely tied to a Florida state-directed payment program (covering October 2024–June 2026) that CMS approved during the quarter. This swung the full-year SPP assumption from a previously expected $(50)–(250) million net decline to a $300–500 million net benefit.
Net-net, the exchange deterioration outpaced the one-time Medicaid benefit, forcing a guidance reset:
| FY2026 Guidance | Prior (Jan 27) | Revised (Jul 14) |
|---|---|---|
| Revenue | $76.5–80.0B | $77.0–79.5B |
| Net income | $6.495–7.035B | $6.3–6.7B |
| Adjusted EBITDA | $15.55–16.45B | $15.4–16.1B |
| Diluted EPS | $29.10–31.50 | $28.70–30.50 |
| Capex | $5.0–5.5B | Unchanged |
That's roughly a $0.40–$1.00 cut to the EPS range midpoint, and the market reaction (a ~$35+ share price decline, ~9%) suggests investors read this as more than a one-off — they're worried about the trajectory of ACA-related deterioration heading into 2027, especially with enhanced premium tax credits (EPTCs) expiring.
On the April Q1 call, management similarly attributed a shortfall (respiratory season/winter storm, ~$180M drag) to temporary factors while flagging that exchange-related volume erosion (~15% decline in exchange-equivalent admissions) was "generally in line" with the original $600–900M full-year assumption. That assumption held for one quarter and then broke materially in Q2 — a dynamic worth watching, since management has now twice had to explain unplanned swings tied to two volatile, hard-to-forecast line items: Medicaid supplemental payments (approval-dependent, lumpy) and ACA exchange dynamics (policy-dependent, evolving in real time as EPTCs lapse).
Investors will want to hear on the call whether the July 14 guidance cut fully captures the deterioration, or whether — like Q1 — this could prove to be another moving target.
The signal is mixed, which is exactly why the call matters: - Tenet Healthcare (THC) reported a Q2 beat and raised full-year guidance on July 23 — a day before HCA's call — citing strong same-store revenue growth and cost control, alongside a $2B buyback increase. That's a notable divergence from HCA's cut and suggests execution/market-mix differences may matter as much as sector-wide ACA pressure. - Molina Healthcare, a payer, also flagged Marketplace medical cost ratio weakness even as it beat overall and raised guidance — corroborating that ACA marketplace stress is a real, multi-company phenomenon, not unique to HCA. - The guidance cut has been described as reigniting the Washington debate over ACA subsidies, since the practical effect of expiring enhanced premium tax credits is now showing up concretely in hospital financials.
Key question for the call: why did Tenet not see the same magnitude of exchange-driven payer-mix pressure? Expect analysts to press on geographic/market exposure differences, exchange penetration by state, and HCA's specific mix of Florida/Texas/other Southeastern markets where ACA marketplace enrollment is heavily concentrated.
Even amid the guidance cut, HCA's capital return machine has kept running. Diluted share count fell from 241.9 million to 222.8 million year-over-year (Q2), reflecting aggressive buybacks. In Q1 alone, the company repurchased $1.57 billion of stock and paid $183 million in dividends, while cash flow from operations rose 22% YoY to $2 billion. Leverage remained in the lower half of the company's target range as of Q1. With the stock down ~30% from its 2026 highs, watch for commentary on whether buyback pace accelerates opportunistically — a potentially important offset to EPS-guidance concerns, and a lever management leaned on to help cushion the multiple contraction.
HCA goes into this print with the "surprise" already out of the bag — Q2 topped estimates on revenue and EPS, but a materially worse-than-expected ACA exchange impact forced a guidance cut that spooked the market more than the in-line quarter reassured it. The stock's ~20% YTD decline and ~30% pullback from 2026 highs reflect a market pricing in structural risk from ACA subsidy expiration rather than one-off noise. The July 24 call is the venue where management needs to draw a credible line between "temporal" and "structural" — something it has now had to do in back-to-back quarters — while reassuring investors that the $1.0–1.2B exchange headwind is fully captured and that peers like Tenet's stronger print doesn't imply HCA-specific execution issues. Capital returns (buybacks) remain a real offsetting positive, but the multiple compression suggests the market wants more clarity on 2027 before re-rating the stock.